Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELATIVITY-073
2023-503519-13-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 2, randomised, open-label trial of nivolumab and relatlimab in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Primary endpoint: Overall response rate (BICR, RECIST v1.1). Started Dec 2020; status: completed.
02
Drugs
nivolumabrelatlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-503519-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503519-13-00.